Indications -- Asthma/Allergy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Asthma/Allergy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	2/27/2004 5:33:17 AM
From: nigel bates	of 86

ALTANA Pharma Receives First Approval to Market Alvesco-R- -Ciclesonide- Friday February 27, 3:59 am ET BAD HOMBURG, Germany--(BUSINESS WIRE)--Feb. 27, 2004--ALTANA AG (NYSE:AAA - News; FWB:ALT) announced today that the Australian Health Agency (TGA) has granted marketing approval for Alvesco® (Ciclesonide) a novel inhaled corticosteroid for the treatment of asthma in adults and adolescents 12 years of age and older. This is worldwide the first approval for Alvesco®. "Alvesco® is an innovative inhaled corticosteroid with unique properties that offer an important treatment option for patients with asthma. The approval of Alvesco® is a major milestone for ALTANA Pharma and we eagerly anticipate making the product available to patients in other important markets as well," said Dr. Hans-Joachim Lohrisch, Member of the Management Board of ALTANA AG and CEO of ALTANA Pharma. In the U.K., the reference member state for the EU regulatory procedure, we expect the final approval in the near future before mid of the year. Additionally, ALTANA's U.S. partner Aventis applied to the FDA for approval of the asthma drug Alvesco® at the end of 2003. ALTANA Pharma and Aventis signed an agreement in 2001 to jointly develop and market Alvesco® in the United States. Finally, Teijin has submitted an application for approval for Alvesco® in January 2004 in Japan. The cooperation agreement with Teijin was signed in 1998 for marketing Alvesco® in Japan. Alvesco® is a new generation inhaled corticosteroid with novel pharmacokinetics properties. Inhaled corticosteroids are considered to be the cornerstone of asthma treatment, and they work by reducing inflammation - the underlying disease process - in the lungs and airways.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next